Media & News | Bioxcellence | Boehringer Ingelheim
Stay updated with BioXcellence Media & News. Explore the latest industry trends & news in global biopharmaceutical contract manufacturing. Don't miss out!
Search
Partnering in Technologies HP SEPT 2024 CORP_0.pdf
Partnering in Technologies AH MAY 2024 CORP.pdf
Angels SD4G_Infografik_2024 Final (1).pdf
Partnering in Oncology & Cancer Imm HP OCTOBER 2024 CORP.pdf
Partnering in RBB HP OCTOBER CORP.pdf
Partnering in Biotherapeutics HP OCTOBER 2024 CORP_1.pdf
Partnering in Technologies HP OCTOBER 2024 CORP.pdf
Iclepertin: GlyT1 inhibitor
Iclepertin: GlyT1 inhibitor
The ANGELS infographic showcasing global stroke care improvements.pdf
C3-binding polypeptide
C3-binding polypeptide
Global Network | Bioxcellence | Boehringer Ingelheim
Our network of manufacturing facilities spans the globe, from Fremont, in the United States to Biberach in Germany, Vienna in Austria and Shanghai in China
Infographic: ANGELS Initiative
C3-binding polypeptide
Partnering in Mental Health Disorders HP OCTOBER 2024 CORP.pdf
Partnering in Cardio-Renal-Metabolic HP OCTOBER 2024 CORP.pdf
Partnering in Immunology & Resp HP OCTOBER 2024 CORP.pdf
Angels_SD4G_Infografik_2024_Final.pdf
Human Health Partnering Interests
Human Health Partnering Interests
Boehringer Ingelheim - Life Forward
Learn how we change life for the better for people and animals.
Isabel
In this video, Isabel shares how watching her children and grandchildren grow up inspires her to take the necessary steps to manage her life with type 2 diabetes and heart disease.
Equestrian sports horse health awareness Alex Hua Tian
Together with Olympian trailblazer and eventer Alex Hua Tian, we educate about equine health in China.
preserved-heart-failure-treatment-FDA-US-approval
US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
Phase II trials for patients with bronchiectasis
Bronchiectasis is a chronically progressive pulmonary disease. Boehringer Ingelheim investigates a potential new treatment option in two Phase II trials.
CHMP recommends new treatment for chronic kidney disease
The CHMP of EMA has granted a positive opinion recommending empagliflozin for the treatment of adults with chronic kidney disease